Atlas FDA

Clinical Chemistry Phosphorus in vitro diagnostic, List Number: 7D71-30 and 7D71-20

FDA device recall Z-0722-2007 · posted 2007-04-05 · Terminated

Recall details

Recalling firm
Abbott Laboratories Inc.
Reason for recall
Patient results are falsely decreased by up to 15% at these levels: 1) Serum Plasma phosphorus greater than 8.0 mg/dL (2.60 mmol/L) 2) Urine phosphorus greater than 80.0 mg/dL (25.80 mmol/L)
Action taken
A Product Correction letter dated January 30, 2007 provided to all Clinical Chemistry Phosphorus customers that have received lot numbers 42020HW00 and 44037HW00 stating that patient results are falsely decreased by up to 15% at these levels: Serum/Plasma phosphorus greater than 8.0 mgldL (2.60 mmol/L) and Urine phosphorus greater than 80.0 mg/dl. (25.80 mmol/L). Modified linearity ranges are provided in the letter that are to be implemented when using the two lots. Instructions are also provided for changing the linearity range on the Architect cSystem as well as the Aeroset System. Customers are instructed that If they have forwarded any of Information the Clinical Chemistry Phosphorus lots listed above to another laboratory to provide a copy of this letter to them. A customer response form is provided.
Root cause
Other
Status
Terminated
Product code
CEO
Quantity affected
42020HW00 - 1,351 units worldwide; 44037HW00 - 314 units worldwide
Distribution
Worldwide, including USA, Canada, Trinidad & Tobago, Bahamas, Panama, Cayman Islands, Jamaica
Date initiated
2007-01-30
Date posted
2007-04-05
Date terminated
2011-08-10
Location
South Pasadena, CA

Monitor recalls programmatically

Recalls and clearances share one API, with change alerts when new recalls post.

Related 510(k) clearances

RecordFirmDate
PHOS (K981759)Abbott Laboratories1998-06-16